Literature DB >> 8688326

C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.

A Travis1, S E Pinder, J F Robertson, J A Bell, P Wencyk, W J Gullick, R I Nicholson, D N Poller, R W Blamey, C W Elston, I O Ellis.   

Abstract

A series of 346 patients with primary operable breast cancer and a series of 145 patients with advanced breast cancer were investigated for c-erbB-3 protein expression using the monoclonal antibody RTJ1. Formalin-fixed, paraffin-embedded tumour samples were stained using a standard immunochemical method and staining was assessed on a four-point scale. The study aimed to observe the expression of the c-erbB-3 protein and investigate any relationship between expression and established prognostic indicators and prognosis. In both the primary and advanced series breast tumour tissue was found to stain heterogeneously for c-erbB-3. The staining was observed to be predominantly cytoplasmic and the majority of tumours exhibited moderate positivity. However, 15% and 35% of cases in the primary operable and advanced series respectively displayed strong positive staining. No significant difference was found between the staining in the primary and advanced series. In the primary operable breast cancers, no significant associations were demonstrated with overall survival, disease-free interval, regional recurrence, the presence of distant metastases, age, menopausal status, oestrogen receptor status, histological grade, lymph node stage, vascular invasion and c-erbB-2 protein expression. However, a significant association was seen between the degree of c-erbB-3 immunoreactivity and both tumour size (P < 0.01) and tumour type prognostic group (P = 0.05). No overall association with local recurrence was seen when the four groups of c-erbB-3 expression were analysed (P = 0.12), but when those tumours showing no or weak staining were compared with those showing moderate and strong immunoreactivity it was seen that the latter were significantly more likely to develop local recurrence (P = 0.03). In the series of patients with advanced disease, no significant associations were demonstrated with survival, UICC criteria, age, menopausal status, oestrogen receptor status, histological grade, c-erbB-2 status or the presence of vascular invasion. In conclusion this study found variable expression of c-erbB-3 protein in human breast carcinoma and an association with some recognised prognostic factors in those patients with primary operable breast carcinoma. It seems, however, unlikely that c-erbB-3 protein expression will emerge as a powerful enough prognostic factor to be of value in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8688326      PMCID: PMC2074568          DOI: 10.1038/bjc.1996.342

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.

Authors:  C Wright; B Angus; S Nicholson; J R Sainsbury; J Cairns; W J Gullick; P Kelly; A L Harris; C H Horne
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

2.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

3.  Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure.

Authors:  S Nicholson; C Wright; J R Sainsbury; P Halcrow; P Kelly; B Angus; J R Farndon; A L Harris
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

4.  Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma.

Authors:  H Pereira; S E Pinder; D M Sibbering; M H Galea; C W Elston; R W Blamey; J F Robertson; I O Ellis
Journal:  Histopathology       Date:  1995-09       Impact factor: 5.087

5.  Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.

Authors:  J R Sainsbury; J R Farndon; G K Needham; A J Malcolm; A L Harris
Journal:  Lancet       Date:  1987-06-20       Impact factor: 79.321

6.  Prognostic value of epidermal growth factor receptor in node-positive breast cancer.

Authors:  M Grimaux; S Romain; Y Remvikos; P M Martin; H Magdelénat
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872

7.  c-erbB-2 oncoprotein expression in primary and advanced breast cancer.

Authors:  C Lovekin; I O Ellis; A Locker; J F Robertson; J Bell; R Nicholson; W J Gullick; C W Elston; R W Blamey
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

8.  An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer.

Authors:  R A Walker; W J Gullick; J M Varley
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

9.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.

Authors:  W J Gullick; S B Love; C Wright; D M Barnes; B Gusterson; A L Harris; D G Altman
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

10.  A prognostic index in primary breast cancer.

Authors:  J L Haybittle; R W Blamey; C W Elston; J Johnson; P J Doyle; F C Campbell; R I Nicholson; K Griffiths
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

View more
  44 in total

Review 1.  The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.

Authors:  Anne W Hamburger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-19       Impact factor: 2.673

2.  Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors.

Authors:  Ellen Q Ingalla; Jamie K Miller; Jessica H Wald; Heather C Workman; Rouminder P Kaur; Lily Yen; William H D Fry; Alexander D Borowsky; Lawrence J T Young; Colleen Sweeney; Kermit L Carraway
Journal:  J Biol Chem       Date:  2010-07-13       Impact factor: 5.157

3.  Inhibition of the HER2 pathway by n-3 polyunsaturated fatty acids prevents breast cancer in fat-1 transgenic mice.

Authors:  Zuquan Zou; Sandrine Bellenger; Karen A Massey; Anna Nicolaou; Audrey Geissler; Célia Bidu; Bernard Bonnotte; Anne-Sophie Pierre; Mélaine Minville-Walz; Michaël Rialland; John Seubert; Jing X Kang; Laurent Lagrost; Michel Narce; Jérôme Bellenger
Journal:  J Lipid Res       Date:  2013-09-19       Impact factor: 5.922

Review 4.  The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

Authors:  Dhara N Amin; Marcia R Campbell; Mark M Moasser
Journal:  Semin Cell Dev Biol       Date:  2010-09-09       Impact factor: 7.727

5.  Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4.

Authors:  A J Lodge; J J Anderson; W J Gullick; B Haugk; R C F Leonard; B Angus
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

6.  The epidermal growth factor receptor family in breast cancer.

Authors:  Angelos K Koutras; T R Jeffry Evans
Journal:  Onco Targets Ther       Date:  2008-09-01       Impact factor: 4.147

Review 7.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

Authors:  José Baselga; Sandra M Swain
Journal:  Nat Rev Cancer       Date:  2009-06-18       Impact factor: 60.716

Review 8.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

9.  Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.

Authors:  Hui Lyu; Jingcao Huang; Susan M Edgerton; Ann D Thor; Zhimin He; Bolin Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

10.  Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.

Authors:  A K Koutras; K T Kalogeras; M-A Dimopoulos; R M Wirtz; U Dafni; E Briasoulis; D Pectasides; H Gogas; C Christodoulou; G Aravantinos; G Zografos; E Timotheadou; P Papakostas; H Linardou; E Razis; T Economopoulos; H P Kalofonos; G Fountzilas
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.